Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 5/2012

01-10-2012 | Small Intestine (J Sellin, Section Editor)

Autoimmune Enteropathy: A Review and Update of Clinical Management

Authors: Nicole M. Gentile, Joseph A. Murray, Darrell S. Pardi

Published in: Current Gastroenterology Reports | Issue 5/2012

Login to get access

Abstract

Autoimmune enteropathy (AIE) is a rare condition characterized by intractable diarrhea, histologic changes on small intestinal biopsy, and failed response to dietary manipulation that also may present with extraintestinal manifestations. In many patients, immunosuppressive therapies are necessary. Although AIE is more common in infants, adult involvement has also been documented. Much of what is known about AIE has been gathered from case reports and small case series; therefore, more research in this evolving field is needed. IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked syndrome) and APECED (autoimmune phenomena, polyendocrinopathy, candidiasis, and ectodermal dystrophy) are systemic forms of AIE.
Literature
1.
•• Akram S, Murray JA, Pardi DS, et al. Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clin Gastroenterol Hepatol. 2007;5:1282–90. A relatively large experience with adult AIE.
2.
•• Montalto M, D'Onofrio F, Santoro L, et al. Autoimmune enteropathy in children and adults. Scand J Gastroenterol. 2009;44:1029–36. Thorough review of the most important aspects of AIE including epidemiology, pathophysiology, clinical features, histopathology, diagnosis, and treatment.
3.
Bishu S, Arsenescu V, Lee EY, et al. Autoimmune enteropathy with a CD8+ CD7- T-cell small bowel intraepithelial lymphocytosis: case report and literature review. BMC Gastroenterol. 2011;11:131.PubMedCrossRef
4.
Hartfield D, Turner J, Huynh H, et al. The role of histopathology in diagnosing protracted diarrhea of infancy. Fetal Pediatr Pathol. 2010;29:144–1457.PubMedCrossRef
5.
Unsworth DJ, Walker-Smith JA. Autoimmunity in diarrhoeal disease. J Pediatr Gastroenterol Nutr. 1985;4:375–80.PubMedCrossRef
6.
• Quiros BA, Sanz AE, Ordiz BE, Garrote Adrados JA, et al. From autoimmune enteropathy to the IPEX (immune dysfunction, polyendocrinopathy, enteropathy, X-linked) syndrome. Allergol Immunopathol. 2009;37:208–15. Discusses the pathophysiology of AIE as well as IPEX, FOXP3, and immune function including T regulatory cell involvement.
7.
Hill SM, Milla PJ, Bottazzo GF, et al. Autoimmune enteropathy and colitis: is there a generalised autoimmune gut disorder? Gut. 1991;32:36–42.PubMedCrossRef
8.
Russo PA, Brochu P, Seidman EG, Roy CC, et al. Autoimmune enteropathy. Pediatr Dev Pathol. 1999;2:65–71.PubMedCrossRef
9.
Volta U, De Angelis GL, Granito A, et al. Autoimmune enteropathy and rheumatoid arthritis: a new association in the field of autoimmunity. Dig Liver Dis. 2006;38:926–9.PubMedCrossRef
10.
11.
Mais DD, Mulhall BP, Adolphson KR, Yamamoto K. Thymoma-associated autoimmune enteropathy. A report of two cases. Am J Clin Pathol. 1999;112:810–5.
12.
Elwing JE, Clouse RE. Adult-onset autoimmune enteropathy in the setting of thymoma successfully treated with infliximab. Dig Dis Sci. 2005;50:928–32.PubMedCrossRef
13.
Wildin RS, Freitas A. IPEX and FOXP3: clinical and research perspectives. J Autoimmun. 2005;25(Suppl):56–62.PubMedCrossRef
14.
Moes N, Rieux-Laucat F, Begue B, et al. Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology. 2010;139:770–8.PubMedCrossRef
15.
Perheentupa J. APS-I/APECED: the clinical disease and therapy. Endocrinol Metabol Clin NA. 2002;31:295–320, vi.
16.
• Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: known and novel aspects of the syndrome. Ann N Y Acad Sci. 2011;1246:77–91. Recent overview of the rare APECED syndrome.
17.
Veress B, Franzén L, Bodin L, Borch K, et al. Duodenal intraepithelial lymphocyte-count revisited. Scand J Gastroenterol. 2004;39:138–44.PubMedCrossRef
18.
León F, Olivencia P, Rodríguez-Pena R, et al. Clinical and immunological features of adult-onset generalized autoimmune gut disorder. Am J Gastroenterol. 2004;99:1563–71.PubMedCrossRef
19.
Gonzalez G, Castro FP, Berho M, Petras R, et al. Autoimmune enteropathy associated with cessation of interferon-alpha therapy in chronic hepatitis C. Dig Dis Sci. 2010;55:1490–3.PubMedCrossRef
20.
Patey-Mariaud de Serre N, Canioni D, Ganousse S, et al. Digestive histopathological presentation of IPEX syndrome. Mod Pathol. 2009;22:95–102.
21.
Unsworth J, Hutchins P, Mitchell J, et al. Flat small intestinal mucosa and autoantibodies against the gut epithelium. J Pediatr Gastroenterol Nutr. 1982;1:503–13.PubMedCrossRef
22.
Skogh T, Heuman R, Tagesson C. Anti-brush border antibodies (ABBA) in Crohn's disease. J Clin Lab Immunol. 1982;9:147–50.PubMed
23.
Martín-Villa JM, Camblor S, Costa R, Arnaiz -Villena et al. Gut epithelial cell autoantibodies in AIDS pathogenesis. Lancet 1993;342:380.
24.
Verpy E, Leibovici M, Zwaenepoel I, et al. A defect in harmonin, a PDZ domain-containing protein expressed in the inner ear sensory hair cells, underlies Usher syndrome type 1C. Nature Gen. 2000;26:51–5.CrossRef
25.
Biagi F, Bianchi PI, Trotta L, Corazza GR. Anti-goblet cell antibodies for the diagnosis of autoimmune enteropathy? Am J Gastroenterol. 2009;104:3112.PubMedCrossRef
26.
Colletti RB, Guillot AP, Rosen S, et al. Autoimmune enteropathy and nephropathy with circulating anti-epithelial cell antibodies. J Pediatr. 1991;118:858–64.PubMedCrossRef
27.
Kobayashi I, Imamura K, Yamada M, et al. A 75-kD autoantigen recognized by sera from patients with X-linked autoimmune enteropathy associated with nephropathy. Clin Exper Immunol. 1998;111:527–31.CrossRef
28.
Bitner-Glindzicz M, Lindley KJ, Rutland P, et al. A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene. Nature Gen. 2000;26:56–60.CrossRef
29.
Kobayashi I, Kubota M, Yamada M, et al. Autoantibodies to villin occur frequently in IPEX, a severe immune dysregulation, syndrome caused by mutation of FOXP3. Clin Immunol. 2011;141:83–9.PubMedCrossRef
30.
Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–61.PubMedCrossRef
31.
Hashimura Y, Nozu K, Kanegane H, et al. Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Pediatric Nephrol. 2009;24:1181–6.CrossRef
32.
Sanderson IR, Phillips AD, Spencer J, Walker-Smith JA, et al. Response to autoimmune enteropathy to cyclosporin A therapy. Gut. 1991;32:1421–5.PubMedCrossRef
33.
Ranta A, Mokanahalli R. Cerebral venous thrombosis in autoimmune enteropathy. New Zeal Med J. 2010;123:108–10.PubMed
Metadata
Title
Autoimmune Enteropathy: A Review and Update of Clinical Management
Authors
Nicole M. Gentile
Joseph A. Murray
Darrell S. Pardi
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Gastroenterology Reports / Issue 5/2012
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-012-0276-2

Other articles of this Issue 5/2012

Current Gastroenterology Reports 5/2012 Go to the issue

Large Intestine (B Cash, Section Editor)

Antibiotics for Irritable Bowel Syndrome: Rationale and Current Evidence

Large Intestine (B Cash, Section Editor)

The Chronic Gastrointestinal Consequences Associated With Campylobacter

Large Intestine (B Cash, Section Editor)

Diagnosis and Differential Diagnosis of Crohn’s Disease of the Ileal Pouch

Small Intestine (J Sellin, Section Editor)

Novel Treatments for NEC: Keeping IBD in Mind

Large Intestine (B Cash, Section Editor)

Familial Colon Cancer Syndromes: an Update of a Rapidly Evolving Field

Small Intestine (J Sellin, Section Editor)

Clinical Implications of Enteroadherent Escherichia coli
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits